Trial Profile

Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirdametinib (Primary) ; Dacomitinib; Docetaxel
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms M13DAP

Most Recent Events

07 Jul 2025 Status changed from recruiting to completed.
09 Mar 2020 Results published in the British Journal of Cancer
08 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com